Login
$AYTU
$2.61 +$0.79 (43.43%) After hours

$AYTU SEC Filings

Filed On Filing
16 Nov 2026 10-Q
16 Nov 2026 8-K: Results of Operations and Financial Condition

(Address of principal executive offices, including zip code)

27 Oct 2026 FORM DEFA14A
22 Oct 2026 Proxy statement: annual meeting on December 10, 2026

CEO pay $845K, down 4.4% · say-on-pay vote

22 Sep 2026 FORM 10-K
22 Sep 2026 8-K: Results of Operations and Financial Condition

Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarter

14 Aug 2026 SCHEDULE 13G/A
30 Jul 2026 Form 4: Disbrow Joshua R., Director

Received 30,000 shares as a grant or award

30 Jul 2026 Form 4: Pyszczymuka Greg, Chief Commercial Officer

Received 20,000 shares as a grant or award

30 Jul 2026 Form 4: Disbrow Jarrett, Chief Business Officer

Received 15,000 shares as a grant or award

30 Jul 2026 Form 4: Selhorn Ryan J, Chief Financial Officer

Received 25,000 shares as a grant or award

30 Jul 2026 Form 4: Liu Vivian H, Director

Received 10,000 shares as a grant or award

30 Jul 2026 Form 4: Jain Abhinav, Director

Received 10,000 shares as a grant or award

30 Jul 2026 Form 4: Dockery Carl, Director

Received 10,000 shares as a grant or award

30 Jul 2026 Form 4: Donofrio John Jr., Director

Received 10,000 shares as a grant or award

25 Jun 2026 8-K: Termination of a Material Definitive Agreement

On June 23, 2026, Aytu BioPharma, Inc. (the “Company”) and Lannett Company, Inc. (together with its affiliates, “Lannett”) mutually agreed to terminate, effective as of June 23, 2026, that certain exclusive license agreement entered into...

13 May 2026 FORM 10-Q
13 May 2026 8-K: Results of Operations and Financial Condition

EXXUA -- with only a partial quarter of full sales force support -- contributed $2.4 million in net revenue supported by rapid monthly compounding script growth rates

02 Apr 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more

Number of Shares of Common Stock or Exchange Warrants: (the “Total Amount”)

17 Feb 2026 SCHEDULE 13G/A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support